The Advisory Committee on Immunization Practice recently made a decision to postpone a vote on delaying infants’ first hepatitis B vaccine, which was a relief to many who were concerned about the potential impact on controlling the spread of the disease. The committee, after a thorough deliberation, decided to table the vote due to ambiguity surrounding the safety, effectiveness, and timing of the vaccine.
Robert Malone, a committee member, expressed his belief that more discussion was needed before a final decision could be made. The majority of the committee agreed, except for chair Martin Kulldorff, who voted to delay the vote. The concern was raised that delaying the vaccine could lead to fewer children receiving the full hepatitis B vaccine series, potentially increasing the risk of harm without any evidence of benefit.
The vote, originally scheduled for Thursday, was postponed to address a discrepancy in how the recommendation aligned with the Vaccines for Children program, which provides vaccines to uninsured or Medicaid-covered children. The specifics of how this discrepancy will be resolved were not disclosed.
In a separate vote, the committee recommended that children under 4 receive the measles, mumps, rubella, and varicella vaccines separately, rather than the combined MMRV vaccine. This decision will impact the availability of low-cost or free vaccines for some children, but separate MMR and varicella shots will now be offered. The committee later moved to align the recommendation for the split vaccine for children covered by VFC.
While CDC studies have shown the hepatitis B vaccine to be safe and effective, some committee members questioned the data and expressed concerns about the long-term safety of the vaccine. Vicky Pebsworth highlighted higher rates of irritability and fussiness in babies who received the vaccine, suggesting potential neurological issues that need further investigation. However, CDC studies have not found any increased risk of neurological problems associated with the vaccine.
In a separate recommendation, the committee voted for all pregnant individuals to be tested for hepatitis B, although some experts questioned the committee’s authority over testing protocols.
Overall, the decision to postpone the vote on delaying the hepatitis B vaccine reflects the committee’s commitment to thorough research and deliberation before making significant recommendations that could impact public health.
